Check Monthly chart. GILD is one of the fastest growing company, but had to drop their share price since Hillary want to drop Drug price. She keep repeating since last year, but it will not really damage drug price. It will actually damage CVS or insurance companies. GILD rebate a lot of money to CVS and insurance companies. Plus, Chart is very attractive and...
RECENTLY most of the biotech companies are doing bad but somehow this ETF is going up. I saw weakness in technical analysis of monthly charts but weekly and daily needs to go down before shorting. Think this IBB bull will be ashort lived and once broken it will be a free fall zone. Leap options for short side will be a good bet. Don't go short yet but a good...
Either going to bounve, or brake nasty... I think it's going to bounce and then die. Look for neg divergences to short later...
Upcoming FDA decision and Fib retracement
about to break much higher 30m:
Biotech bubble has burst. Every rallies are to be sold, and despite the euphoria/new highs in S&P and Nasdaq have barely registered a decent retracement in the biotech sector.. Here's a larger picture of how far biotechs have went since 2008: The uptrend in S&P is limited, and it will only be a matter of time before it collapses off this rising wedge....
Chart very bullish with strong sentiment and positive press. Should continue to trade in Bullish pattern.
With the new pressure on Bio's upon us I wanted to take a look at a stock I have long liked and especially like at this level. With new patents and a bunch of new drugs in the pipeline it will happen quickly and suddenly. The chart shows great strength as it has held up when others have fallen and I look for a move over the next month to 4.66. All it needs is a...
Sophiris Bio had a Phase III drug trial test showing the drug was not effective and the market overreacted. The chart has a cash/share value (mrq) of $1.74, the float is 16.78 Million Shares (note today's volume alone is a large part of that), so with a tiny float, more cash per share on hand than the market price, and upcoming results for new Phase III results...